Astrocyte-driven suppression of tumor-specific T-cell immunity in glioblastoma
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1032462 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR26535000_1.fastq.gz | Fastqsanger.gz | |||
| SRR26535000_2.fastq.gz | Fastqsanger.gz | |||
| SRR26535001_1.fastq.gz | Fastqsanger.gz | |||
| SRR26535001_2.fastq.gz | Fastqsanger.gz | |||
| SRR26535002_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 204 |
Similar Datasets
Project description:Glioblastoma (GBM) is the most common and aggressive brain cancer, showing minimal response to available therapies. A highly immunosuppressive tumor microenvironment (TME) contributes to the limited therapeutic response of GBM. Astrocytes are major components of the central nervous system (CNS), with important immunoregulatory roles. However, little is known about the role of astrocytes and their subsets in the immune response to GBM. Using single-cell and bulk RNA sequencing in GBM clinical samples and mouse pre-clinical models, in combination with multiplexed immunofluorescence microscopy, in vivo CRISPR-based cell-specific genetic perturbations, and in vitro mouse and human experimental systems we identified an astrocyte subset that limits tumor-specific immunity by inducing CD8+ and CD4+ T-cell apoptosis via the death receptor ligand TRAIL. Moreover, we identified IL-11 produced by tumor cells as a driver of STAT3-dependent TRAIL expression in GBM-associated astrocytes. pSTAT3+ TRAIL+ astrocytes were co-localized with apoptotic T cells in human GBM samples and were associated with a shorter time to recurrence and overall decreased survival in GBM patients. Conversely, genetic inactivation of the IL-11 receptor or TRAIL in astrocytes extended survival in GBM mouse models and boosted tumor-specific T cells and tumor-associated macrophage responses. Finally, a GBM-targeting oncolytic HSV-1 virus engineered to express a TRAIL-blocking single-chain antibody in the TME extended survival and boosted tumor-specific immunity in GBM pre-clinical models. In summary, we established that IL-11/STAT3-driven astrocytes suppress GBM-specific protective immunity by inducing TRAIL-dependent T-cell apoptosis, and we developed engineered therapeutic viruses to target this novel mechanism of astrocyte-driven tumor immunoevasion.
2025-05-21 | GSE246293 | GEO
Project description:With HiRIEF LC-MS/MS shotgun proteomics, we analysed 6 patient-derived glioblastoma stem cells (BT stem cells) and compared them to an astrocyte line (CliniSciences, Guidonia Montecelio, Italy) and a more differentiated glioblastoma cell line (T98G). Each of the 8 cell line sample was run in triplicates in a total of three TMT10 sets, assigning each replicate in a separate TMT10 set, using 2 internal standards per set. The three TMT10 sets were ran in two experiments, first on immobilized pH gradient (IPG) 3-10 isoelectric focusing (IEF) strips, and then on IPG 3.7-4.9 IEF strips.
2022-12-23 | PXD027335 | Pride
Project description:Astrocyte morphology driven improvements to OCD phenotypes
| PRJNA1036677 | ENA
Project description:Glioblastoma (GBM) is defined by heterogenous and resilient cell populations that closely reflect neurodevelopmental cell types. While it is clear that GBM echoes early and immature cell states, identifying the specific developmental programs disrupted in these tumors has been hindered by a lack of high-resolution trajectories of glial and neuronal lineages. Here, we delineate the course of human astrocyte maturation to uncover discrete developmental stages and attributes mirrored by GBM. We generated a transcriptomic and epigenomic map of human astrocyte maturation using cortical organoids maintained in culture for nearly two years. Through this approach, we chronicled a multi-phase developmental process orchestrated by a series of transcription factor and gene regulatory networks. Our time course of human astrocyte maturation includes a novel and molecularly distinct intermediate period that serves as a lineage commitment checkpoint upstream of mature quiescence. This intermediate stage acts as a site of developmental deviation separating IDH-wildtype neoplastic astrocyte lineage cells from quiescent astrocyte populations. Interestingly, IDH1-mutant tumor astrocyte lineage cells are the exception to this developmental perturbation, where immature properties are suppressed as a result of D2HG oncometabolite exposure. We propose that this defiance is likely a consequence of IDH1mt-associated epigenetic dysregulation and we identified biased DNA hydroxymethylation (5hmC) in maturation genes as a possible mechanism. Together, this study illustrates a novel cellular state aberration in GBM astrocyte lineage cells and presents new developmental targets for experimental and therapeutic exploration.
2024-10-31 | GSE276177 | GEO
Project description:Trained immunity suppression determines kidney allograft survival
| PRJNA1180533 | ENA
Project description:Divergence from the human astrocyte developmental trajectory in glioblastoma
| PRJNA1155637 | ENA
Project description:Generate scRNA-Seq profiles for PDGF-driven glioblastoma mouse model.
2018-02-23 | GSE95157 | GEO
Project description:Glioblastoma (GBM) is defined by heterogenous and resilient cell populations that closely reflect neurodevelopmental cell types. While it is clear that GBM echoes early and immature cell states, identifying the specific developmental programs disrupted in these tumors has been hindered by a lack of high-resolution trajectories of glial and neuronal lineages. Here, we delineate the course of human astrocyte maturation to uncover discrete developmental stages and attributes mirrored by GBM. We generated a transcriptomic and epigenomic map of human astrocyte maturation using cortical organoids maintained in culture for nearly two years. Through this approach, we chronicled a multi-phase developmental process orchestrated by a series of transcription factor and gene regulatory networks. Our time course of human astrocyte maturation includes a novel and molecularly distinct intermediate period that serves as a lineage commitment checkpoint upstream of mature quiescence. This intermediate stage acts as a site of developmental deviation separating IDH-wildtype neoplastic astrocyte lineage cells from quiescent astrocyte populations. Interestingly, IDH1-mutant tumor astrocyte lineage cells are the exception to this developmental perturbation, where immature properties are suppressed as a result of D2HG oncometabolite exposure. We propose that this defiance is likely a consequence of IDH1mt-associated epigenetic dysregulation and we identified biased DNA hydroxymethylation (5hmC) in maturation genes as a possible mechanism. Together, this study illustrates a novel cellular state aberration in GBM astrocyte lineage cells and presents new developmental targets for experimental and therapeutic exploration.
2024-10-31 | GSE276103 | GEO
Project description:Glioblastoma (GBM) is defined by heterogenous and resilient cell populations that closely reflect neurodevelopmental cell types. While it is clear that GBM echoes early and immature cell states, identifying the specific developmental programs disrupted in these tumors has been hindered by a lack of high-resolution trajectories of glial and neuronal lineages. Here, we delineate the course of human astrocyte maturation to uncover discrete developmental stages and attributes mirrored by GBM. We generated a transcriptomic and epigenomic map of human astrocyte maturation using cortical organoids maintained in culture for nearly two years. Through this approach, we chronicled a multi-phase developmental process orchestrated by a series of transcription factor and gene regulatory networks. Our time course of human astrocyte maturation includes a novel and molecularly distinct intermediate period that serves as a lineage commitment checkpoint upstream of mature quiescence. This intermediate stage acts as a site of developmental deviation separating IDH-wildtype neoplastic astrocyte lineage cells from quiescent astrocyte populations. Interestingly, IDH1-mutant tumor astrocyte lineage cells are the exception to this developmental perturbation, where immature properties are suppressed as a result of D2HG oncometabolite exposure. We propose that this defiance is likely a consequence of IDH1mt-associated epigenetic dysregulation and we identified biased DNA hydroxymethylation (5hmC) in maturation genes as a possible mechanism. Together, this study illustrates a novel cellular state aberration in GBM astrocyte lineage cells and presents new developmental targets for experimental and therapeutic exploration.
2024-10-31 | GSE276176 | GEO
Project description:Glioblastoma (GBM) is defined by heterogenous and resilient cell populations that closely reflect neurodevelopmental cell types. While it is clear that GBM echoes early and immature cell states, identifying the specific developmental programs disrupted in these tumors has been hindered by a lack of high-resolution trajectories of glial and neuronal lineages. Here, we delineate the course of human astrocyte maturation to uncover discrete developmental stages and attributes mirrored by GBM. We generated a transcriptomic and epigenomic map of human astrocyte maturation using cortical organoids maintained in culture for nearly two years. Through this approach, we chronicled a multi-phase developmental process orchestrated by a series of transcription factor and gene regulatory networks. Our time course of human astrocyte maturation includes a novel and molecularly distinct intermediate period that serves as a lineage commitment checkpoint upstream of mature quiescence. This intermediate stage acts as a site of developmental deviation separating IDH-wildtype neoplastic astrocyte lineage cells from quiescent astrocyte populations. Interestingly, IDH1-mutant tumor astrocyte lineage cells are the exception to this developmental perturbation, where immature properties are suppressed as a result of D2HG oncometabolite exposure. We propose that this defiance is likely a consequence of IDH1mt-associated epigenetic dysregulation and we identified biased DNA hydroxymethylation (5hmC) in maturation genes as a possible mechanism. Together, this study illustrates a novel cellular state aberration in GBM astrocyte lineage cells and presents new developmental targets for experimental and therapeutic exploration.
2024-10-31 | GSE276101 | GEO